JP4623931B2 - 炎症性疾患の治療用組成物 - Google Patents
炎症性疾患の治療用組成物 Download PDFInfo
- Publication number
- JP4623931B2 JP4623931B2 JP2002547474A JP2002547474A JP4623931B2 JP 4623931 B2 JP4623931 B2 JP 4623931B2 JP 2002547474 A JP2002547474 A JP 2002547474A JP 2002547474 A JP2002547474 A JP 2002547474A JP 4623931 B2 JP4623931 B2 JP 4623931B2
- Authority
- JP
- Japan
- Prior art keywords
- liposomes
- corticosteroid
- inflammatory
- vesicle
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
実施例1
リン酸プレドニソロン含有PEG−リポソームの製造
750mgのジパルミトイルホスファチジルコリン(DPPC)(Lipoid Ludwigshafen)、250.8mgのコレステロール(Sigma Aldrich)および267.6mgのPEG−ジステアロイルホスファチジルエタノールアミン(PEG−DSPE)(Avanti Polar Lipids)を秤量し、100mL丸底フラスコで混合した。これらの脂質を約30mLのエタノールに溶解した。その後、Rotavaporにて真空下40℃で1時間、蒸発乾固させた後、1時間窒素ガスでフラッシした。
他の水溶性コルチコステロイド含有PEG−リポソームの製造
リン酸プレドニソロン二ナトリウムの代わりにそれぞれリン酸デキサメタゾン二ナトリウム(OPG Nieuwegein)、リン酸ベタメタゾン二ナトリウム(Sigma-Aldrich)または21−リン酸ブデソニド(Syncom, Groningen, the Netherlands)を用いたこと以外は実施例1を繰り返した。
ラットアジュバント関節炎モデルにおける治療効果の評価
ルイスラットの尾の基部にフロイントの不完全アジュバント中の熱不活化結核菌(Mycobacterium tuberculosis)を皮下感作させた。感作して9〜12日後に脚の炎症が始まり、約20日後に最大重度に達し、その後徐々に消散した。
AT−EAEにおける治療効力の評価
雌ルイスマウスに107MBP特異的T細胞の静脈注射により養子移植実験的自己免疫脳脊髄炎(AT−EAE)を誘導した。実施例1に従って製造した10mg/kgリン酸プレドニソロン含有リポソームを犠牲にする42時間および18時間前に静脈注射した。もう一方の群には灌流18時間および6時間前に50mg/kgメチルプレドニソロンを静脈注射した。対照ラットには同じ時点で空のリポソームおよび/または生理食塩水を施した。脊髄のT細胞またはマクロファージはパラフィン包埋組織にて免疫組織化学的に検出し、アポトーシスはTUNELアッセイにより、また、形態学的基準により評価した。統計分析には分類したデータに関するスチューデントのt検定を用いた。脊髄組織におけるT細胞のアポトーシス率はリン酸プレドニソロンリポソームによって有意に増大した(39.4±6.8%、p<0.0001に対して対照群では16.1±4.3%、データは全て平均値±標準偏差で示される)。内部対照としてのメチルプレドニソロンは30.8±8.0%という率でのT細胞アポトーシスをもたらす(対照に対してp<0.01)。アポトーシスが増大する結果としてT細胞の浸潤はリン酸プレドニソロンリポソームによって明らかに低下した(45±12T細胞/mm2)。なおこれは対照に対して(115±51T細胞/mm2、p<0.05)、およびメチルプレドニソロンに対して(96±19T細胞/mm2、p<0.05)統計学的に有意であった。炎症のもう1つの局面としてのマクロファージの浸潤は対照(78±37マクロファージ/mm2、p<0.05)と比較して、およびメチルプレドニソロン(66±25マクロファージ/mm2、p<0.05)と比較して、リン酸プレドニソロンリポソーム(31±13マクロファージ/mm2)によって有意に低下した。迅速機構の検討を目的に養子移植モデルを選択した場合でも、42時間内にリン酸プレドニソロンリポソームの治療効果が見られ、対照(3.2±0.3、p<0.01)に比べて臨床スコア2.8±0.2に達し、これはメチルプレドニソロン(リン酸プレドニソロンリポソームに対して3.2±0.3、p<0.05)よりも優れていた。
Claims (8)
- 0超過20モル%までのポリエチレングリコール誘導体化両親媒性小胞形成脂質を含んでなる非電荷リポソームを含んでなり、このリポソームが40〜200nmの範囲で選択される平均粒径を有し、かつ、水溶性コルチコステロイドを含んでなる、炎症性疾患の炎症領域治療のための非経口投与用医薬組成物。
- 0超過20モル%までのポリエチレングリコール誘導体化両親媒性小胞形成脂質と0超過10モル%までの負電荷小胞形成脂質とを含んでなる負電荷リポソームを含んでなり、このリポソームが40〜200nmの範囲で選択される平均粒径を有し、かつ、水溶性コルチコステロイドを含んでなる、炎症性疾患の炎症領域治療のための非経口投与用医薬組成物。
- コルチコステロイドが、抗炎症性疾患の全身治療に通常用いられるコルチコステロイドからなる群から選択されることを特徴とする、請求項1または2に記載の組成物。
- 前記コルチコステロイドが、プレドニソロン、デキサメタゾンおよびメチルプレドニソロンからなる群から選択されることを特徴とする、請求項3に記載の組成物。
- コルチコステロイドが、局所用に通常用いられるコルチコステロイドからなる群から選択されることを特徴とする、請求項1または2に記載の組成物。
- 前記コルチコステロイドが、ブデソニド、フルニソリドおよびプロピオン酸フルチカゾンからなる群から選択されることを特徴とする、請求項5に記載の組成物。
- 慢性関節リウマチの炎症領域治療のための、請求項1〜6のいずれか一項に記載の組成物。
- 多発性硬化症の炎症領域治療のための、請求項1〜6のいずれか一項に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00204372 | 2000-12-07 | ||
PCT/EP2001/014633 WO2002045688A2 (en) | 2000-12-07 | 2001-12-07 | Composition for treatment of inflammatory disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004517835A JP2004517835A (ja) | 2004-06-17 |
JP4623931B2 true JP4623931B2 (ja) | 2011-02-02 |
Family
ID=8172392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002547474A Expired - Fee Related JP4623931B2 (ja) | 2000-12-07 | 2001-12-07 | 炎症性疾患の治療用組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7955618B2 (ja) |
EP (1) | EP1347743B1 (ja) |
JP (1) | JP4623931B2 (ja) |
AT (1) | ATE319428T1 (ja) |
AU (2) | AU2002231697B2 (ja) |
CA (1) | CA2430897C (ja) |
DE (1) | DE60117858T2 (ja) |
DK (1) | DK1347743T3 (ja) |
ES (1) | ES2260321T3 (ja) |
PT (1) | PT1347743E (ja) |
WO (1) | WO2002045688A2 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2430897C (en) | 2000-12-07 | 2010-11-16 | Universiteit Utrecht Holding B.V. | Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
EP1371362A1 (en) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
EP1393720A1 (en) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
JPWO2005011633A1 (ja) * | 2003-08-01 | 2006-09-14 | 独立行政法人産業技術総合研究所 | 標的指向性リポソームを含む炎症性疾患治療薬または診断薬 |
US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
US7744920B2 (en) | 2004-09-09 | 2010-06-29 | Hadasit Medical Research Services & Development Limited | Use of liposomal glucocorticoids for treating inflammatory states |
AU2006270165B2 (en) * | 2005-07-14 | 2010-03-11 | Neothetics, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
EP2127639A1 (en) * | 2008-05-26 | 2009-12-02 | Universiteit Utrecht Holding B.V. | Corticosteroid containing liposomes for treatment of cardiovascular diseases |
US20100016265A1 (en) * | 2008-07-16 | 2010-01-21 | Qaiser Yusuf | Anti-inflammatory composition and method for preparation |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
CN102869363A (zh) * | 2010-01-15 | 2013-01-09 | 利赛拉公司 | 冻干的块状制剂 |
SG190878A1 (en) | 2010-11-24 | 2013-07-31 | Lithera Inc | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
AU2012331702B2 (en) * | 2011-11-04 | 2017-10-26 | Laurentia Holding B.V. | Liposomal corticosteroids for treatment of inflammatory disorders in humans |
US9186326B2 (en) * | 2014-07-21 | 2015-11-17 | Kimia Zist Parsian (Kzp) | Method and system for synthesizing nanocarrier based long acting drug delivery system for dexamethasone |
CA2997286A1 (en) * | 2015-09-14 | 2017-03-23 | Vgsk Technologies, Inc. | A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal |
JP2019515925A (ja) | 2016-04-29 | 2019-06-13 | エンセラドゥス ファーマセウティカルス べー.フェー. | 炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002185A (en) * | 1930-06-26 | 1935-05-21 | Prosperity Co Inc | Garment or ironing press |
GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
US4522803A (en) * | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
IL79114A (en) | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
DE3542773A1 (de) * | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | Hautwirksame pharmaka mit liposomen als wirkstofftraeger |
US4818537A (en) * | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5139803A (en) * | 1989-02-09 | 1992-08-18 | Nabisco, Inc. | Method and liposome composition for the stabilization of oxidizable substances |
FR2648462B1 (fr) * | 1989-06-15 | 1994-01-28 | Oreal | Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede |
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
JPH07316040A (ja) * | 1994-03-29 | 1995-12-05 | Res Dev Corp Of Japan | 再構成リポソームと物質導入方法 |
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
JPH08198777A (ja) * | 1995-01-25 | 1996-08-06 | Taisho Pharmaceut Co Ltd | 注射用脂肪乳剤 |
WO1997022903A1 (en) * | 1995-12-15 | 1997-06-26 | Philips Electronics N.V. | Liquid crystal display device |
JPH09278672A (ja) * | 1996-04-12 | 1997-10-28 | Green Cross Corp:The | 薬物含有脂肪乳剤 |
ES2296311T3 (es) * | 1996-06-18 | 2008-04-16 | Kyowa Hakko Kogyo Co., Ltd. | Preparaciones de liposomas de derivados de indolo carbazol. |
ATE252372T1 (de) * | 1996-08-23 | 2003-11-15 | Sequus Pharm Inc | Liposome enthaltend cisplatin |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US5758659A (en) | 1997-03-26 | 1998-06-02 | Thompson; Robert B. | Wound tab condom and method of application |
US20020159951A1 (en) | 1997-05-06 | 2002-10-31 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
AU6974798A (en) | 1997-05-06 | 1998-11-27 | Imarx Pharmaceutical Corp. | Novel prodrugs comprising fluorinated amphiphiles |
US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6316260B1 (en) * | 1997-08-22 | 2001-11-13 | Bernina Biosystems Gmbh | Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraether lipid derivatives, and use thereof |
EP1044679B1 (en) * | 1998-11-02 | 2012-12-26 | Terumo Kabushiki Kaisha | Stable Liposomes for Targeted Drug Delivery |
JP2002533379A (ja) | 1998-12-23 | 2002-10-08 | イデア アクチェンゲゼルシャフト | 生体内における局所的に非侵襲性である用途のための改善された製剤 |
US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
EP1190706B1 (en) | 1999-06-25 | 2009-05-06 | Terumo Kabushiki Kaisha | Liposomes |
HUP0202177A3 (en) * | 1999-07-14 | 2004-05-28 | Alza Corp Mountain View | Neutral lipopolymer and liposomal compositions containing same |
EP1072617A1 (en) | 1999-07-30 | 2001-01-31 | Universiteit van Utrecht | Temperature sensitive polymers |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US20030050236A1 (en) * | 2000-08-15 | 2003-03-13 | The University Of Chicago | Compounds that enhance tumor death |
TWI230616B (en) * | 2000-09-25 | 2005-04-11 | Ind Tech Res Inst | Liposome for incorporating large amounts of hydrophobic substances |
CA2430897C (en) | 2000-12-07 | 2010-11-16 | Universiteit Utrecht Holding B.V. | Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders |
EP1371362A1 (en) | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
EP1393720A1 (en) | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
-
2001
- 2001-12-07 CA CA2430897A patent/CA2430897C/en not_active Expired - Lifetime
- 2001-12-07 AT AT01991836T patent/ATE319428T1/de active
- 2001-12-07 AU AU2002231697A patent/AU2002231697B2/en not_active Ceased
- 2001-12-07 AU AU3169702A patent/AU3169702A/xx active Pending
- 2001-12-07 DE DE60117858T patent/DE60117858T2/de not_active Expired - Lifetime
- 2001-12-07 JP JP2002547474A patent/JP4623931B2/ja not_active Expired - Fee Related
- 2001-12-07 DK DK01991836T patent/DK1347743T3/da active
- 2001-12-07 ES ES01991836T patent/ES2260321T3/es not_active Expired - Lifetime
- 2001-12-07 PT PT01991836T patent/PT1347743E/pt unknown
- 2001-12-07 WO PCT/EP2001/014633 patent/WO2002045688A2/en active IP Right Grant
- 2001-12-07 EP EP01991836A patent/EP1347743B1/en not_active Expired - Lifetime
-
2003
- 2003-06-05 US US10/455,257 patent/US7955618B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE319428T1 (de) | 2006-03-15 |
ES2260321T3 (es) | 2006-11-01 |
AU3169702A (en) | 2002-06-18 |
CA2430897A1 (en) | 2002-06-13 |
EP1347743B1 (en) | 2006-03-08 |
DK1347743T3 (da) | 2006-07-03 |
US20040037875A1 (en) | 2004-02-26 |
CA2430897C (en) | 2010-11-16 |
WO2002045688A2 (en) | 2002-06-13 |
DE60117858T2 (de) | 2006-11-30 |
PT1347743E (pt) | 2006-06-30 |
US7955618B2 (en) | 2011-06-07 |
DE60117858D1 (de) | 2006-05-04 |
AU2002231697B2 (en) | 2006-09-07 |
WO2002045688A3 (en) | 2002-11-14 |
JP2004517835A (ja) | 2004-06-17 |
EP1347743A2 (en) | 2003-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4623931B2 (ja) | 炎症性疾患の治療用組成物 | |
US8932627B2 (en) | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | |
JP4869594B2 (ja) | 癌治療のための小胞封入コルチコステロイド | |
AU2002231697A1 (en) | Composition for treatment of inflammatory disorders | |
US20140255474A1 (en) | Composition for Treatment of Inflammatory Disorders | |
JP6609286B2 (ja) | ヒトにおける炎症性障害の治療用リポソームコルチコステロイド | |
JP4564844B2 (ja) | 炎症性疾患の治療用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041202 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081126 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091002 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091009 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101005 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101102 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4623931 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131112 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |